Aryl Hydrocarbon Receptor Involvement in the Sodium-Dependent Glutamate/Aspartate Transporter Regulation in Cerebellar Bergmann Glia Cells-Reference-Cited by-同舟云学术

Aryl Hydrocarbon Receptor Involvement in the Sodium-Dependent Glutamate/Aspartate Transporter Regulation in Cerebellar Bergmann Glia Cells

Published:2024-03-08 Issue:6 Volume:15 Page:1276-1285
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Silva-Parra Janisse¹,Ramírez-Martínez Leticia¹,Palafox-Gómez Cecilia¹,Sandu Cristina²,López-Bayghen Esther¹,Vega Libia¹,Elizondo Guillermo³,Loaeza-Loaeza Jaqueline¹,Hernández-Sotelo Daniel⁴,Hernández-Kelly Luisa C.¹,Felder-Schmittbuhl Marie-Paule²^ORCID,Ortega Arturo¹^ORCID

Affiliation:

1. Departamento de Toxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Apartado Postal 14-740, Ciudad de México 07360, Mexico

2. Centre National de la Recherche Scientifique, Université de Strasbourg, Institut des Neurosciences Cellulaires et Intégratives, Strasbourg 00000, France

3. Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Apartado Postal 14-740, Ciudad de México 07360, Mexico

4. Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Guerrero, Chilpancingo 39070, Guerrero, Mexico

Funder

Consejo Nacional de Ciencia y Tecnolog?a

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.4c00046

Reference49 articles.

1. Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels

2. The Effect of the Selective N-methyl-D-aspartate (NMDA) Receptor GluN2B Subunit Antagonist CP-101,606 on Cytochrome P450 2D (CYP2D) Expression and Activity in the Rat Liver and Brain

3. Glutamate receptor agonists increase the expression of Fos, Fra, and AP-1 DNA binding activity in the mammalian brain

4. Transcriptional Regulation of Glutamate Transporters

5. Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence?